SBC Medical Moves into Longevity with a Biological Age Test, Backed by a Growing Core Business

The new test combines the Waqoo Group’s regenerative medicine research with SBC Medical’s network of more than 280 clinics, building on a second quarter of 13% revenue growth and a 41% adjusted EBITDA margin.

SBC Medical Group Holdings (Nasdaq: SBC) is developing its own test to estimate a person’s biological age using DNA methylation analysis. The company announced the program on October 22, delivering on the longevity strategy it outlined to investors two months earlier.

Chronological age measures how long someone has been alive, not how their body is actually aging. SBC Medical’s test is designed to measure the second. The company describes the test as a dynamic personal baseline rather than a one-time score, something a customer can measure, act on and measure again.

The Science Behind the Test

DNA methylation is an epigenetic marker. Unlike the underlying genetic code, it shifts with diet, stress, environment and lifestyle, which makes it well suited to tracking change over time. The science has moved quickly since the first landmark epigenetic clock was published in 2013. In 2025, a study in Nature Aging described a way to estimate the ages of 11 distinct organs and physiological systems from a single blood draw.

SBC Medical’s roadmap builds on that work in three directions: mapping biological age by organ system to show where aging-related changes are progressing, researching non-invasive methods that don’t require a blood draw, and building an evaluation framework on Japanese cohort data. The company noted that the biological age test reflects current plans and is subject to change.

The program positions SBC Medical in a broader shift in healthcare from extending lifespan to extending healthspan, the years lived in good health. Citing a Report Ocean study, the company says the global longevity market is projected to grow from about $800 billion in 2025 to about $2 trillion by 2035. As one of the world’s oldest populations, Japan gives SBC Medical a large home market for the test.

Leadership and Scientific Foundation

Development will be led by SBC AI Longevity Innovation, the AI and longevity subsidiary SBC Medical established in July 2026. Its stated mission is to extend human healthspan by combining medicine and AI, drawing on clinical data and experience from a network of more than 280 clinics. The subsidiary launched its first product, the SBC AI Assistant, at Shonan Beauty Clinic on August 26.

The scientific foundation comes from Waqoo, Inc. (TSE: 4937) and its subsidiary, Cell Pro Japan Co., Ltd., which bring cellular and molecular research capabilities from their regenerative medicine operations. SBC Medical acquired a 54% stake in Waqoo in December 2025. The program pairs that research base with the clinic operations and customer experience of SBC Medical’s core business, giving it both scientific depth and a direct path to customers.

Yuya Yoshida, Director, CFO and COO of SBC Medical, leads the initiative as President and Representative Director of SBC AI Longevity Innovation. He is scheduled to speak in the keynote and panel sessions at Cantor Fitzgerald Hong Kong’s inaugural Asia Longevity Forum on October 26. SBC Medical will hold one-on-one investor meetings at the forum on October 27, followed by a non-deal roadshow in Hong Kong on October 28. Presentation materials will be posted on the company’s IR website.

Core Business Momentum

The longevity program is backed by a growing and highly profitable core business. In the second quarter of 2026, revenue rose 13% year over year to $49 million, and adjusted EBITDA, a non-GAAP measure, rose 32% to $20 million, a 41% margin.

“Having completed the structural reforms we undertook in 2025, we are now running multiple growth engines simultaneously,” Chairman and CEO Yoshiyuki Aikawa said in the second-quarter release.

SBC Medical’s support and partnership network reached 287 locations at June 30, up 34 from a year earlier. Visits over the trailing twelve months totaled 6.9 million, up 10%, and average spend per visit rose 9% to $287.

SBC Medical is also putting more than 26 years of management data to work in AI-powered call centers, marketing and site selection for new clinics. Management expects fee revisions tied to call center services and expanded support for Rize Clinic and Gorilla Clinic to add about $15 million in annual service fees if realized for a full year, converted at ¥158.1 to the dollar.

In aesthetics, the company added NEO Skin Clinic, opening in Nagoya on August 22 and in Kobe, its first location in the Kansai region, on August 29. The new brand joins Shonan Beauty Clinic, Hada no Aozora Clinic, Shonan Beauty Clinic THE LASER and SBC MEN’S FLASH CLINIC. Management calls its non-aesthetic business its “second growth engine,” and it plans to accelerate international growth through its collaboration with OrangeTwist in the United States and an ASEAN expansion anchored in Thailand.

SBC Medical funds these initiatives from a strong balance sheet, with $184 million in cash and cash equivalents at June 30 and $31.7 million in operating cash flow in the first half, giving the company the capacity to invest in longevity while continuing to expand its core business.

Share this article:

Disclaimer

This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

About the Author:

PubMatic, Viant and Digital Turbine Grew Up to 29%. Here’s Where Advertisers Are Spending.

Editor Prism MarketView

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup